Mild stroke and rapidly improving symptoms: It's not always a happy ending

Stroke

Volumn 42, Issue 11, 2011, Pages 3005-3007

  Balucani, Clotilde ^a,b   Levine, Steven R ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT;

ACUTE ISCHEMIC STROKE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HUMAN; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

HAPPINESS; HUMANS; INFUSIONS, INTRAVENOUS; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 80054999151     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.628701     Document Type: Review

References (29)

1. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 45 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: A science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945-2948.
4. Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: A population-based study. Stroke. 2004;35:27-29.
5. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: A doubling of treatment rates over the course of 5 years. Stroke. 2011;42: 1952-1955.
6. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from tPA therapy? an analysis of patient eligibility. Neurology. 2001;56:1015-1020. (Pubitemid 32336306)
7. George MG, Tong X, McGruder H, Yoon P, Rosamond W, Winquist A, et al. Centers for Disease Control and Prevention (CDC). Coverdell National Acute Stroke Registry Surveillance-four states, 2005-2007. MMWR Surveill Summ. 2009;6:58:1-23.
8. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. J Am Med Assoc. 2000;283:1151-1158. (Pubitemid 30126603)
9. Smith EE, Abdullah AR, Petkovska I, Rosenthal E, Koroshetz WJ, Schwamm LH. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke. 2005;36:2497-2499. (Pubitemid 41566987)
10. Schumacher HC, Bateman BT, Boden-Albala B, Berman MF, Mohr JP, Sacco RL, et al. Use of thrombolysis in acute ischemic stroke: analysis of the nationwide inpatient sample 1999 to 2004. Ann Emerg Med. 2007; 50:99-107. (Pubitemid 47079072)
11. Smith EE, Fonarow GC, Reeves MJ, Cox M, Olson DWM, Hernandez AF, Schwamm L, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke. 2011;42: 3110-3115.
12. LaBresh KA, Reeves MJ, Frankel MR, Albright D, Schwamm LH. Hospital treatment of patients with ischemic stroke or transient ischemic attack using the 'Get With The Guidelines' program. Arch Intern Med. 2008;168:411-417. (Pubitemid 351347133)
13. Nedeltchev K, Schwegler B, Haefeli T, Brekenfeld C, Gralla J, Fischer U, et al. Outcome of stroke with mild or rapidly improving symptoms. Stroke. 2007;38:2531-2535. (Pubitemid 47329633)
14. Genentech. Medicines: product information: Activase-(Alteplase) http://www.gene.com/gene/products/information/cardiovascular/activase/insert. jsp. Accessed July 7, 2011.
15. Khatri P, Kleindorfer DO, Yeatts SD, Saver JL, Levine SR, Lyden PD, et al. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials. Stroke. 2010;41:2581-2586. 15a.Fischer U, Baumgartner A, Arnold M, Nedeltcheu K, Gralla J, De Marchis CM, et al. What is a minor stroke? Stroke. 2010;41:661-666.
16. Dirks M, Niessen LW, Koudstaal PJ, Franke CL, van Oostenbrugge RJ, Dippel DW; Delphi panel on indications and contraindications for intravenous thrombolysis in acute ischaemic stroke. Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications: an international Delphi study. J Neurol Neurosurg Psychiatry. 2007;78:685-689. (Pubitemid 46998835)
17. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation. 2007;115:478-534.
18. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: A clinical examination scale. Stroke. 1989;20:964-970.
19. Martin-Schild S, Albright KC, Tanksley J, Pandav V, Jones EB, Grotta JC, et al. Zero on the NIHSS does not equal the absence of stroke. Ann Emerg Med. 2011;57:42-45.
20. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med. 2005;46:243-252.
21. Dirks M, Niessen LW, van Wijngaarden JD, Koudstaal PJ, Franke CL, van Oostenbrugge RJ, et al, for the PRomoting ACute Thrombolysis in Ischemic stroke (PRACTISE) Investigators. Promoting thrombolysis in acute ischemic stroke. Stroke. 2011;42:1325-1330.
22. Rajajee V, Kidwell C, Starkman S, Ovbiagele B, Alger JR, Villablanca P, et al. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology. 2006;67:980-984. (Pubitemid 44454588)
23. Alexandrov AV, Felberg RA, Demchuk AM, Christou I, Burgin WS, Malkoff M, et al. Deterioration following spontaneous improvement: sonographic findings in patients with acutely resolving symptoms of cerebral ischemia. Stroke. 2000;31:915-919. (Pubitemid 30198438)
24. Coutts SB, O'Reilly C, Hill MD, Steffenhagen N, Poppe AY, Boyko MJ, et al. Computed tomography and computed tomography angiography findings predict functional impairment in patients with minor stroke and transient ischaemic attack. Int J Stroke. 2009;4:448-453.
25. Baumann CR, Baumgartner RW, Gandjour J, von Büdingen HC, Siegel AM, Georgiadis D. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke. 2006;37:1332-1333. (Pubitemid 43731885)
26. Kohrmann M, Nowe T, Huttner HB, Engelhorn T, Struffert T, Kollmar R, et al. Safety and outcome after thrombolysis in stroke patients with mild symptoms. Cerebrovasc Dis. 2009;27:160-166.
27. Hassan AE, Hassanzadeh B, Tohidi V, Kirmani JF. Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage. South Med J. 2010;103:398-402.
28. Levine SR, Khatri P, Khoury J, Saver JL, Broderick JP. Rapidly improving stroke symptoms: A controversial exclusion criterion for tPA. Stroke. 2011;42:e86.
29. Khatri P, Khoury JC, Alwell K, Moomaw CJ Kissela BM, Woo D, et al. The public health impact of an effective acute treatment for mild ischemic strokes. Stroke. 2011;42:e66.